The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Open accessAbstract
The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have mutations in the GBA gene, making it numerically the most important genetic risk factor for Parkinson disease (PD). Clinically, GBA-associated PD is identical to sporadic PD, aside from the earlier age at onset (AAO), more frequent cognitive impairment and more rapid progression. Mutations in GBA can be associated with loss- and gain-of-function mechanisms. A key hallmark of PD is the presence of intraneuronal proteinaceous inclusions named Lewy bodies, which are made up primarily of alpha-synuclein. Mutations in the GBA gene may lead to loss of GCase activity and lysosomal dysfunction, which may impair alpha-synuclein metabolism. Models of GCase deficiency demonstrate dysfunction of the autophagic-lysosomal pathway and subsequent accumulation of alpha-synuclein. This dysfunction can also lead to aberrant lipid metabolism, including the accumulation of glycosphingolipids, glucosylceramide and glucosylsphingosine. Certain mutations cause GCase to be misfolded and retained in the endoplasmic reticulum (ER), activating stress responses including the unfolded protein response (UPR), which may contribute to neurodegeneration. In addition to these mechanisms, a GCase deficiency has also been associated with mitochondrial dysfunction and neuroinflammation, which have been implicated in the pathogenesis of PD. This review discusses the pathways associated with GBA-PD and highlights potential treatments which may act to target GCase and prevent neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 3×
“proposed a sequential model of Lewy body formation and deposition of alpha-synuclein [18].”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Autophagy as a Regulated Pathway of Cellular Degradation
Klionsky, D. J., & Emr, S. D. (2000) · Science · doi:10.1126/science.290.5497.1717 · Cited by 3,608
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Self-citationMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Self-citationLewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Self-citationMazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., & Vekrellis, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5699-09.2010 · Cited by 1,115
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033
Grazia Spillantini, M., Anthony Crowther, R., Jakes, R., Cairns, N. J., Lantos, P. L., & Goedert, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00504-7 · Cited by 1,025
Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes
Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., Castaño-Díez, D., Schweighauser, G., Graff-Meyer, A., Goldie, K. N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0423-2 · Cited by 996
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Self-citationKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J. A., & Cooper, J. M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.029 · Cited by 748
Self-citationGlucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Phenotype, diagnosis, and treatment of Gaucher's disease
Grabowski, G. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61522-6 · Cited by 634
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
The Gaucher Registry: Demographics and Disease Characteristics of 1698 Patients With Gaucher Disease
Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Weinreb, N. J., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2835 · Cited by 574
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
Self-citationChaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 554
Self-citationSchöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 543
LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase
Reczek, D., Schwake, M., Schröder, J., Hughes, H., Blanz, J., Jin, X., Brondyk, W., Van Patten, S., Edmunds, T., & Saftig, P. (2007) · Cell · doi:10.1016/j.cell.2007.10.018 · Cited by 542
The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders
Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., & Takahashi, H. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8280-y · Cited by 479
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475
Autophagy and neurodegeneration: when the cleaning crew goes on strike
Martinez-Vicente, M., & Cuervo, A. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70076-5 · Cited by 474
Neuropathology provides clues to the pathophysiology of Gaucher disease
Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G. D., Wakefield, L. K., Morrison, A., Lwin, A., Colegial, C., Allman, J. M., et al. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.04.011 · Cited by 452
Survival and dementia in GBA ‐associated Parkinson's disease: The mutation matters
Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A. L., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 406
Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
Alcalay, R. N., Levy, O. A., Waters, C. H., Fahn, S., Ford, B., Kuo, S.-H., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan-Or, Z., et al. (2015) · Brain · doi:10.1093/brain/awv179 · Cited by 392
Fabelo, N., Martín, V., Santpere, G., Marín, R., Torrent, L., Ferrer, I., & Díaz, M. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00119 · Cited by 379
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Glucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Differential effects of severe vs mild GBA mutations on Parkinson disease
Gan-Or, Z., Amshalom, I., Kilarski, L. L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., & Orr-Urtreger, A. (2015) · Neurology · doi:10.1212/wnl.0000000000001315 · Cited by 364
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset
Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., & Orr-Urtreger, A. (2008) · Neurology · doi:10.1212/01.wnl.0000304039.11891.29 · Cited by 360
Marsden, C. D. (1990) · The Lancet · doi:10.1016/0140-6736(90)91006-v · Cited by 357
Mullin, S., Smith, L., Lee, K., D’Souza, G., Woodgate, P., Elflein, J., Hällqvist, J., Toffoli, M., Streeter, A., Hosking, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4611 · Cited by 356
Self-citationFernandes, H. J. R., Hartfield, E. M., Christian, H. C., Emmanoulidou, E., Zheng, Y., Booth, H., Bogetofte, H., Lang, C., Ryan, B. J., Sardi, S. P., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.01.013 · Cited by 351
Schöndorf, D. C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., Giunta, I., Schwarz, L. K., Di Napoli, G., Panagiotakopoulou, V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.009 · Cited by 337
Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Londt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 334
Self-citationIdentification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012393 · Cited by 332
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
Ron, I., & Horowitz, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi240 · Cited by 330
Tayebi, N. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00071-4 · Cited by 327
McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Self-citationSardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
Galvagnion, C., Brown, J. W. P., Ouberai, M. M., Flagmeier, P., Vendruscolo, M., Buell, A. K., Sparr, E., & Dobson, C. M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601899113 · Cited by 308
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 307
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Winder-Rhodes, S. E., Evans, J. R., Ban, M., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Duran, R., Mencacci, N. E., Sawcer, S. J., & Barker, R. A. (2013) · Brain · doi:10.1093/brain/aws318 · Cited by 290
Loria, F., Vargas, J. Y., Bousset, L., Syan, S., Salles, A., Melki, R., & Zurzolo, C. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1746-2 · Cited by 289
Lesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C., Viallet, F., Lohmann, E., Corvol, J.-C., Honoré, A., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq454 · Cited by 287
Nilsson, O., & Svennerholm, L. T. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb07950.x · Cited by 283
X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease
Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., & Sussman, J. L. (2003) · EMBO reports · doi:10.1038/sj.embor.embor873 · Cited by 278
Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N. J., Jeon, S., Burbulla, L. F., Patnaik, S., Sidransky, E., Marugan, J. J., Sue, C. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0628-16.2016 · Cited by 273
Lipid droplets in neurodegenerative disorders
Farmer, B. C., Walsh, A. E., Kluemper, J. C., & Johnson, L. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00742 · Cited by 270
GBA-associated PD presents with nonmotor characteristics
Brockmann, K., Srulijes, K., Hauser, A.-K., Schulte, C., Csoti, I., Gasser, T., & Berg, D. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab77 · Cited by 268
Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., & Berg, D. (2015) · Movement Disorders · doi:10.1002/mds.26071 · Cited by 267
Lee, E.-J., Woo, M.-S., Moon, P.-G., Baek, M.-C., Choi, I.-Y., Kim, W.-K., Junn, E., & Kim, H.-S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903480 · Cited by 267
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study
Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M.-X., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 262
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease
Thome, A. D., Harms, A. S., Volpicelli-Daley, L. A., & Standaert, D. G. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3900-15.2016 · Cited by 247
Mistry, P. K., Liu, J., Yang, M., Nottoli, T., McGrath, J., Jain, D., Zhang, K., Keutzer, J., Chuang, W.-L., Mehal, W. Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003308107 · Cited by 245
Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N., & Cox, T. M. (1997) · QJM · doi:10.1093/qjmed/90.1.19 · Cited by 245
Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease
Taguchi, Y. V., Liu, J., Ruan, J., Pacheco, J., Zhang, X., Abbasi, J., Keutzer, J., Mistry, P. K., & Chandra, S. S. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1525-17.2017 · Cited by 243
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., & Brice, A. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f476 · Cited by 238
Blauwendraat, C., Reed, X., Krohn, L., Heilbron, K., Bandres-Ciga, S., Tan, M., Gibbs, J. R., Hernandez, D. G., Kumaran, R., Langston, R., et al. (2020) · Brain · doi:10.1093/brain/awz350 · Cited by 236
Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., & Schapira, A. H. V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw185 · Cited by 234
Self-citationThe relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
Self-citationGlucocerebrosidase mutations are an important risk factor for Lewy body disorders
Goker-Alpan, O., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M.-Y., Trojanowski, J. Q., & Sidransky, E. (2006) · Neurology · doi:10.1212/01.wnl.0000230215.41296.18 · Cited by 230
Aflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 227
The risk of Parkinson's disease in type 1 Gaucher disease
Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9055-0 · Cited by 223
Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
Zunke, F., Moise, A. C., Belur, N. R., Gelyana, E., Stojkovska, I., Dzaferbegovic, H., Toker, N. J., Jeon, S., Fredriksen, K., & Mazzulli, J. R. (2018) · Neuron · doi:10.1016/j.neuron.2017.12.012 · Cited by 223
Woodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
Alcalay, R. N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W. K., Pauciulo, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.313 · Cited by 217
Davis, M. Y., Johnson, C. O., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2245 · Cited by 215
Progressive decline of glucocerebrosidase in aging and Parkinson's disease
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., & Isacson, O. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.177 · Cited by 210
Glucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders
Mata, I. F., Samii, A., Schneer, S. H., Roberts, J. W., Griffith, A., Leis, B. C., Schellenberg, G. D., Sidransky, E., Bird, T. D., Leverenz, J. B., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.68 · Cited by 207
Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation–Positive Cohort
Beavan, M., McNeill, A., Proukakis, C., Hughes, D. A., Mehta, A., & Schapira, A. H. V. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2950 · Cited by 205
Self-citationAmbroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
Migdalska‐Richards, A., Daly, L., Bezard, E., & Schapira, A. H. V. (2016) · Annals of Neurology · doi:10.1002/ana.24790 · Cited by 204
Self-citationGlucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage
Cleeter, M. W. J., Chau, K.-Y., Gluck, C., Mehta, A., Hughes, D. A., Duchen, M., Wood, N. W., Hardy, J., Mark Cooper, J., & Schapira, A. H. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.010 · Cited by 201
Self-citationGaucher Disease and Parkinsonism: A Phenotypic and Genotypic Characterization
Tayebi, N., Callahan, M., Madike, V., Stubblefield, B. K., Orvisky, E., Krasnewich, D., Fillano, J. J., & Sidransky, E. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3201 · Cited by 200
The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations
Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M., & Sidransky, E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1353 · Cited by 199
Murine models of acute neuronopathic Gaucher disease
Enquist, I. B., Bianco, C. L., Ooka, A., Nilsson, E., Månsson, J.-E., Ehinger, M., Richter, J., Brady, R. O., Kirik, D., & Karlsson, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708086104 · Cited by 198
Orvisky, E., Park, J. K., LaMarca, M. E., Ginns, E. I., Martin, B. M., Tayebi, N., & Sidransky, E. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00117-8 · Cited by 193
Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line
Alvarez-Erviti, L., Couch, Y., Richardson, J., Cooper, J. M., & Wood, M. J. A. (2011) · Neuroscience Research · doi:10.1016/j.neures.2010.12.020 · Cited by 193
Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M., & Futerman, A. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21673 · Cited by 183
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 181
GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers
Kim, S., Yun, S. P., Lee, S., Umanah, G. E., Bandaru, V. V. R., Yin, X., Rhee, P., Karuppagounder, S. S., Kwon, S.-H., Lee, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700465115 · Cited by 178
Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein
Bae, E.-J., Yang, N.-Y., Song, M., Lee, C. S., Lee, J. S., Jung, B. C., Lee, H.-J., Kim, S., Masliah, E., Sardi, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms5755 · Cited by 177
Manning-Boğ, A. B., Schüle, B., & Langston, J. W. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.06.009 · Cited by 176
Nagata, M., Izumi, Y., Ishikawa, E., Kiyotake, R., Doi, R., Iwai, S., Omahdi, Z., Yamaji, T., Miyamoto, T., Bamba, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618133114 · Cited by 172
Mitochondrial Contribution to Parkinson's Disease Pathogenesis
Schapira, A. H. V., & Gegg, M. E. (2011) · Parkinson s Disease · doi:10.4061/2011/159160 · Cited by 169
Self-citationThe taming of the cell penetrating domain of the HIV Tat: Myths and realities
Chauhan, A., Tikoo, A., Kapur, A. K., & Singh, M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.031 · Cited by 169
Huebecker, M., Moloney, E. B., van der Spoel, A. C., Priestman, D. A., Isacson, O., Hallett, P. J., & Platt, F. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0339-z · Cited by 165
RIPK3 as a potential therapeutic target for Gaucher's disease
Vitner, E. B., Salomon, R., Farfel-Becker, T., Meshcheriakova, A., Ali, M., Klein, A. D., Platt, F. M., Cox, T. M., & Futerman, A. H. (2014) · Nature Medicine · doi:10.1038/nm.3449 · Cited by 164
Farfel‐Becker, T., Vitner, E. B., Kelly, S. L., Bame, J. R., Duan, J., Shinder, V., Merrill, A. H., Dobrenis, K., & Futerman, A. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt468 · Cited by 164
Kinghorn, K. J., Grönke, S., Castillo-Quan, J. I., Woodling, N. S., Li, L., Sirka, E., Gegg, M. E., Mills, K. A., Hardy, J., Bjedov, I., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4527-15.2016 · Cited by 163
Rocha, E. M., Smith, G. A., Park, E. Y. H., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J. A., Izen, S. C., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 162
Khanna, R., Benjamin, E. R., Pellegrino, L., Schilling, A., Rigat, B. A., Soska, R., Nafar, H., Ranes, B. E., Feng, J., Lun, Y., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07588.x · Cited by 161
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., Beagan, J., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 160
Exploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 160
Rosenbloom, B., Balwani, M., Bronstein, J. M., Kolodny, E., Sathe, S., Gwosdow, A. R., Taylor, J. S., Cole, J. A., Zimran, A., & Weinreb, N. J. (2011) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.10.006 · Cited by 158
Sanchez-Martinez, A., Beavan, M., Gegg, M. E., Chau, K.-Y., Whitworth, A. J., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep31380 · Cited by 158
Self-citationMoors, T. E., Paciotti, S., Ingrassia, A. M. T., Quadri, M., Breedveld, G. J., Tasegian, A., Chiasserini, D., Eusebi, P., Durán-Pacheco, G., Kremer, T., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1090-0 · Cited by 158
Kuo, S.-H., Tasset, I., Cheng, M. M., Diaz, A., Pan, M.-K., Lieberman, O. J., Hutten, S. J., Alcalay, R. N., Kim, S., Ximénez-Embún, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6393 · Cited by 153
Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa‐Akanbi, M., Chinnery, P. F., Morris, C. M., Calabresi, P., Parnetti, L., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0010-2 · Cited by 152
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult
Henderson, M. X., Sedor, S. F., McGeary, I., Cornblath, E. J., Peng, C., Riddle, D. M., Li, H. L., Zhang, B., Brown, H. J., Olufemi, M. F., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.12.004 · Cited by 152
Acid β-Glucosidase: Enzymology and Molecular Biology of Gaucher Diseas
Grabowski, G. A., Gaft, S., Horowitz, M., & Kolodny, E. H. (1990) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239009090616 · Cited by 150
Vitner, E. B., Farfel-Becker, T., Eilam, R., Biton, I., & Futerman, A. H. (2012) · Brain · doi:10.1093/brain/aws095 · Cited by 149
Durán, R., Mencacci, N. E., Angeli, A., Shoai, M., Deas, E., Houlden, H., Mehta, A. B., Hughes, D. A., Cox, T. M., Deegan, P. B., et al. (2012) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 147
Self-citationAmbroxol as a pharmacological chaperone for mutant glucocerebrosidase
Bendikov-Bar, I., Maor, G., Filocamo, M., et al. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.10.007 · Cited by 147
Gaucher Disease: Clinical, Biological and Therapeutic Aspects
Dandana, A., Khelifa, S. B., Chahed, H., Miled, A., & Ferchichi, S. (2015) · Pathobiology · doi:10.1159/000440865 · Cited by 146
Alpha-synuclein aggregation involves a bafilomycin A1-sensitive autophagy pathway
Klucken, J., Poehler, A.-M., Ebrahimi‐Fakhari, D., Schneider, J., Nuber, S., Rockenstein, E. M., Schlötzer-Schrehardt, U. M., Hyman, B. T., McLean, P. J., Masliah, E., et al. (2012) · Autophagy · doi:10.4161/auto.19371 · Cited by 143
No evidence for substrate accumulation in Parkinson brains with GBA mutations
Gegg, M. E., Sweet, L., Wang, B. H., Shihabuddin, L. S., Sardi, S. P., & Schapira, A. H. V. (2015) · Movement Disorders · doi:10.1002/mds.26278 · Cited by 142
Self-citationPetrucci, S., Ginevrino, M., Trezzi, I., Monfrini, E., Ricciardi, L., Albanese, A., Avenali, M., Barone, P., Bentivoglio, A. R., Bonifati, V., et al. (2020) · Movement Disorders · doi:10.1002/mds.28195 · Cited by 141
Morabito, G., Giannelli, S. G., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M. T., Cabassi, T., Cattaneo, S., Luoni, M., Cancellieri, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.004 · Cited by 140
Patnaik, S., Zheng, W., Choi, J. H., Motabar, O., Southall, N. T., Westbroek, W., Lea, W., Velayati, A., Goldin, E., Sidransky, E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300063b · Cited by 139
Xu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D. P., & Grabowski, G. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.12.014 · Cited by 139
Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.
Grace, M., Newman, K., Scheinker, V., Berg-Fussman, A., & Grabowski, G. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42166-1 · Cited by 138
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Zimran, A., Altarescu, G., & Elstein, D. (2013) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2012.09.006 · Cited by 136
Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
Malek, N., Weil, R. S., Bresner, C., Lawton, M., Grosset, K. A., Tan, M. M. X., Bajaj, N. P. S., Barker, R. A., Burn, D. J., Foltynie, T., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317348 · Cited by 136
Yun, S. P., Kim, D., Kim, S., Kim, S., Karuppagounder, S. S., Kwon, S., Lee, S., Kam, T., Lee, S.-H., Ham, S., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0233-5 · Cited by 134
Du, T., Wang, L., Duan, C., Lu, L., Zhang, J., Gao, G., Qiu, X., Wang, X., & Yang, H. (2015) · Autophagy · doi:10.1080/15548627.2015.1086055 · Cited by 132
The role of glucocerebrosidase in Parkinson disease pathogenesis
Gegg, M. E., & Schapira, A. H. V. (2018) · FEBS Journal · doi:10.1111/febs.14393 · Cited by 132
Self-citationKeatinge, M., Bui, H. H., Menke, A. L., Chen, Y., Sokòl, A. M., Bai, Q., Ellett, F. E., Costa, M. D., Burke, D. G., Gegg, M. E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv369 · Cited by 131
Self-citationAnalyses of Variant Acid β-Glucosidases
Liou, B., Kazimierczuk, A., Zhang, M., Scott, C. R., Hegde, R. S., & Grabowski, G. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511110200 · Cited by 130
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Atashrazm, F., Hammond, D. A., Perera, G., Dobson‐Stone, C., Mueller, N., Pickford, R., Kim, W. S., Kwok, J. B., Lewis, S. J. G., Halliday, G. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33921-x · Cited by 130
Moloney, E. B., Moskites, A., Ferrari, E. J., Ole Isacson, A., & Hallett, P. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.013 · Cited by 129
Stojkovska, I., Wani, W. Y., Zunke, F., Belur, N. R., Pavlenko, E. A., Mwenda, N., Sharma, K., Francelle, L., & Mazzulli, J. R. (2021) · Neuron · doi:10.1016/j.neuron.2021.10.032 · Cited by 128
Enzyme replacement and substrate reduction therapy for Gaucher disease
Shemesh, E., Deroma, L., Bembi, B., Deegan, P. B., Hollak, C. E. M., Weinreb, N. J., & Cox, T. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010324.pub2 · Cited by 127
Cavaliere, F., Cerf, L., Dehay, B., Ramos‐Gonzalez, P., Giorgi, F. D., Bourdenx, M., Bessede, A., Obeso, J. A., Matute, C., Ichas, F., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.011 · Cited by 123
Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation
Fishbein, I., Kuo, Y., Giasson, B. I., & Nussbaum, R. L. (2014) · Brain · doi:10.1093/brain/awu291 · Cited by 122
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
Migdalska‐Richards, A., Ko, W. K. D., Li, Q., Bézard, E., & Schapira, A. H. V. (2017) · Synapse · doi:10.1002/syn.21967 · Cited by 122
Self-citationLoss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation
Bae, E.-J., Yang, N. Y., Lee, C.-S., Lee, H.-J., Kim, S., Sardi, S. P., & Lee, S. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.128 · Cited by 121
Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant
Bendikov-Bar, I., Ron, I., Filocamo, M., & Horowitz, M. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.10.012 · Cited by 119
Ginns, E. I., Mak, S. K., Ko, N., Karlgren, J., Akbarian, S., Chou, V., Guo, Y., Lim, A., Samuelsson, S. J., LaMarca, M. L., et al. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.003 · Cited by 115
A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
Richter, F., Fleming, S. M., Watson, M. B., Lemesre, V., Pellegrino, L. J., Ranes, B. E., Zhu, C., Mortazavi, F., Mulligan, C. K., Sioshansi, P. C., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0294-x · Cited by 114
Unfolded protein response in Gaucher disease: from human to Drosophila
Maor, G., Rencus‐Lazar, S., Filocamo, M., Steller, H., Segal, D., & Horowitz, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-140 · Cited by 114
McNeill, A., Durán, R., Hughes, D. A., Mehta, A. B., & Schapira, A. H. V. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302402 · Cited by 111
Self-citationWinfield, S. L., Tayebi, N., Martin, B. M., Ginns, E. I., & Sidransky, E. (1997) · Genome Research · doi:10.1101/gr.7.10.1020 · Cited by 108
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease
Ziegler, S. G., Eblan, M. J., Gutti, U., Hruska, K. S., Stubblefield, B. K., Göker-Alpan, Ö., LaMarca, M. E., & Sidransky, E. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.03.004 · Cited by 107
Jo, J., Yang, L., Tran, H., Yu, W., Sun, A. X., Chang, Y. Y., Jung, B. C., Lee, S., Saw, T. Y., Xiao, B., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26166 · Cited by 105
Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population
Horowitz, M., Pasmanik‐Chor, M., Borochowitz, Z. U., Zaccai, T. C. F., Heldmann, K., Carmi, R., Parvari, R., Beit-Or, H., Goldman, B., Peleg, L., et al. (1998) · Human Mutation · Cited by 99
Serum lipid alterations in GBA-associated Parkinson's disease
Guedes, L. C., Chan, R., Gomes, M. A., Conceição, V. A., Machado, R. B., Soares, T., Xu, Y., Gaspar, P., Carriço, J. A., Alcalay, R. N., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.08.026 · Cited by 98
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice
Xu, Y., Xu, K., Sun, Y., Liou, B., Quinn, B., Li, R.-H., Xue, L., Zhang, W., Setchell, K. D. R., Witte, D. P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu105 · Cited by 96
GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis
Mallett, V. M., Ross, J. P., Alcalay, R. N., Ambalavanan, A., Sidransky, E., Dion, P. A., Rouleau, G. A., & Gan‐Or, Z. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000104 · Cited by 96
Wang, F., Song, W., Brancati, G., & Segatori, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274332 · Cited by 95
Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
Magalhães, J., Gegg, M. E., Migdalska‐Richards, A., & Schapira, A. H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-19479-8 · Cited by 95
Self-citationStoker, T. B., Camacho, M., Winder‐Rhodes, S., Liu, G., Scherzer, C. R., Foltynie, T., Evans, J., Breen, D. P., Barker, R. A., & Williams‐Gray, C. H. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322857 · Cited by 93
Lu, J., Yang, C., Chen, M., Ye, D. Y., Lonser, R. R., Brady, R. O., & Zhuang, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119181109 · Cited by 90
Montfort, M., Amparo Chabás, B., Vilageliu, L., & Grinberg, D. (2004) · Human Mutation · doi:10.1002/humu.20043 · Cited by 88
Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
Galvagnion, C., Marlet, F. R., Cerri, S., Schapira, A. H. V., Blandini, F., & Monte, D. A. D. (2021) · Brain · doi:10.1093/brain/awab371 · Cited by 86
Self-citationHallett, P. J., Huebecker, M., Brekk, O. R., Moloney, E. B., Rocha, E. M., Priestman, D. A., Platt, F. M., & Ole Isacson, A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.028 · Cited by 85
A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease
Aflaki, E., Stubblefield, B. K., McGlinchey, R. P., McMahon, B., Ory, D. S., & Sidransky, E. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104647 · Cited by 81
Insights into the structural biology of Gaucher disease
Smith, L., Mullin, S., & Schapira, A. H. V. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.010 · Cited by 79
Self-citationGBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes
Greuel, A., Trezzi, J., Glaab, E., Ruppert, M. C., Maier, F., Jäger, C., Hodak, Z., Lohmann, K., Ma, Y., Eidelberg, D., et al. (2020) · Movement Disorders · doi:10.1002/mds.28225 · Cited by 79
Gündner, A. L., Durán-Pacheco, G., Zimmermann, S., Ruf, I., Moors, T. E., Baumann, K., Jagasia, R., van de Berg, W. D. J., & Kremer, T. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.015 · Cited by 78
Peterschmitt, M., Saiki, H., Hatano, T., Gasser, T., Isaacson, S., Gaemers, S. J., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212714 · Cited by 78
Self-citationThe L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
Migdalska‐Richards, A., Węgrzynowicz, M., Rusconi, R., Deangeli, G., Monte, D. A. D., Spillantini, M. G., & Schapira, A. H. V. (2017) · Brain · doi:10.1093/brain/awx221 · Cited by 77
Self-citationYang, C., Rahimpour, S., Lu, J., Pacák, K., Ikejiri, B. L., Brady, R. O., & Zhuang, Z. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221046110 · Cited by 76
LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease
Gan‐Or, Z., Bar‐Shira, A., Mirelman, A., Gurevich, T., Kedmi, M., Giladi, N., & Orr‐Urtreger, A. (2009) · Neurogenetics · doi:10.1007/s10048-009-0198-9 · Cited by 75
Fu, A., Wang, Y., Zhan, L., & Zhou, R. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0667-y · Cited by 73
The contribution of mutantGBAto the development of Parkinson disease inDrosophila
Maor, G., Cabasso, O., Krivoruk, O., Rodriguez, J., Steller, H., Segal, D., & Horowitz, M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw129 · Cited by 73
Yang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 73
Self-citationGlucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
Kurzawa‐Akanbi, M., Hanson, P. S., Blain, P. G., Lett, D. J., McKeith, I. G., Chinnery, P. F., & Morris, C. M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07879.x · Cited by 72
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations
Choi, J. H., Stubblefield, B. K., Cookson, M., Goldin, E., Velayati, A., Tayebi, N., & Sidransky, E. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.008 · Cited by 71
Clark, L. N., Chan, R., Cheng, R., Liu, X., Park, N., Parmalee, N. L., Kisselev, S., Cortes, E. P., Torres, P., Pastores, G. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125204 · Cited by 68
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands
den Heijer, J. M., Cullen, V., Quadri, M., Schmitz, A., Hilt, D. C., Lansbury, P. T., Berendse, H. W., van de Berg, W. D. J., de Bie, R. M. A., Boertien, J. M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28112 · Cited by 68
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease
Ruskey, J. A., Greenbaum, L., Roncière, L., Alam, A., Spiegelman, D., Liong, C., Levy, O. A., Waters, C., Fahn, S., Marder, K. S., et al. (2018) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2018.05.005 · Cited by 66
Jung, O., Patnaik, S., Marugán, J., Sidransky, E., & Westbroek, W. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1174583 · Cited by 63
The Oligomer Hypothesis in α-Synucleinopathy
Ono, K. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2382-x · Cited by 62
Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons
Gegg, M. E., Verona, G., & Schapira, A. H. V. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa085 · Cited by 62
Self-citationA Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C
Lieberman, R. L. (2011) · Enzyme Research · doi:10.4061/2011/973231 · Cited by 59
Lipid composition of microdomains is altered in a cell model of Gaucher disease
Hein, L. K., Duplock, S. K., Hopwood, J. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800092-jlr200 · Cited by 58
Dermentzaki, G., Dimitriou, E., Xilouri, M., Michelakakis, H., & Stefanis, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060674 · Cited by 56
Glucocerebrosidase mutations in diffuse Lewy body disease
Nishioka, K., Ross, O. A., Vilariño‐Güell, C., Cobb, S. A., Kachergus, J. M., Mann, D. M. A., Snowden, J. S., Richardson, A. M. T., Neary, D., Robinson, C. A., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.009 · Cited by 55
Murugesan, V., Liu, J., Yang, R., Lin, H., Lischuk, A., Pastores, G., Zhang, X.-K. K., Chuang, W.-L., & Mistry, P. (2016) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2016.12.002 · Cited by 55
Berge‐Seidl, V., Pihlstrøm, L., Maple‐Grødem, J., Forsgren, L., Linder, J., Larsen, J. P., Tysnes, O., & Toft, M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.08.040 · Cited by 55
mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats
Decressac, M., & Björklund, A. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120155 · Cited by 54
The enigma of the E326K mutation in acid β-glucocerebrosidase
Horowitz, M., Pasmanik‐Chor, M., Ron, I., & Kolodny, E. H. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.002 · Cited by 54
Yang, S., Gegg, M. E., Chau, D., & Schapira, A. H. V. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104620 · Cited by 53
Self-citationGillmeister, M. P., Betenbaugh, M. J., & Fishman, P. S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc900445g · Cited by 52
Neurological involvement in type 1 (adult) Gaucher's disease.
McKeran, R. O., Bradbury, P. G., Taylor, D., & Stern, G. M. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.2.172 · Cited by 52
Fog, C. K., Zago, P., Malini, E., Solanko, L. M., Peruzzo, P., Bornæs, C., Magnoni, R., Mehmedbašić, A., Petersen, N. H. T., Bembi, B., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.037 · Cited by 50
β-Glucocerebrosidase activity in GBA -linked Parkinson disease
Huh, Y. E., Chiang, M. S. R., Locascio, J. J., Liao, Z., Liu, G., Choudhury, K., Kuras, Y. I., Tuncali, I., Videnović, A., Hunt, A. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009989 · Cited by 49
den Heijer, J. M., Kruithof, A. C., van Amerongen, G., de Kam, M. L., Thijssen, E., Grievink, H. W., Moerland, M., Walker, M., Been, K., Skerlj, R. T., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14772 · Cited by 47
Thomas, R. E., Vincow, E. S., Merrihew, G. E., MacCoss, M. J., Davis, M. Y., & Pallanck, L. J. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007694 · Cited by 46
Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease
Parkkinen, L., Neumann, J., O’Sullivan, S. S., Holton, J. L., Révész, T., Hardy, J., & Lees, A. J. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.04.015 · Cited by 45
Paul, A., Jacoby, G., Bar‐Yosef, D. L., Beck, R., Gazit, E., & Segal, D. (2021) · ACS Nano · doi:10.1021/acsnano.1c02957 · Cited by 44
Cited by
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Metadata
- Authors
- Smith, L., & Schapira, A. H. V.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 11
- Issue
- 8
- Pages
- 1261
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4224297855
- Cited by
- 256
- References
- 221
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.